Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness

Recruiting now · Phase 2

Conditions studied: Severe Aplastic Anemia, Platelet Transfusion Refractoriness

In brief

Due to long-term dependence on platelet transfusion, some severe aplastic anemia (SAA) patients suffer platelet transfusion refractoriness (PTR). Unlike immune thrombocytopenia (ITP), glucocorticoids and human immunoglobulin (IVIg) are generally ineffective for PTR. Due to the lack of effective intervention methods, patients with PTR suffer increased platelet transfusions, bleeding events and treatment costs, prolonged hospital stays, and decreased survival rate. SAA with PTR has become a challenge for physicians. The experiment aims to explore the efficacy of rituximab in the treatment of SAA with PTR, and establish a new effective, safe treatment method with relatively low treatment cost.

Key facts

Study ID

NCT06254560

Run by

Institute of Hematology & Blood Diseases Hospital, China

People needed

20

Starts

2023-02-23

Expected to finish

2027-12-30

Last updated by the study team

2024-02-12

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Initial diagnosed SAA with PTR
• Age>18 years old, regardless of gender
• Initial diagnosed SAA with PTR
• Age>18 years old, regardless of gender

You may not qualify if…

• Allergy to rituximab
• Severe active infection
• Hypogammaglobulinemia
• Pregnant and lactating women
• Heart failure (NYHA classification IV)
• Individuals with epilepsy, dementia, and other mental disorders that require medication treatment who cannot understand or follow the research protocol
• Chronic infections or other chronic diseases that may be risk to the experiment
• The researchers believe that it is not suitable for participants

Where it is running

• Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences — Tianjin, Tianjin Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.